Cargando…
Feasibility, acceptability, and utility of a nurse-led survivorship program for people with metastatic melanoma (MELCARE)
PURPOSE: Immune checkpoint inhibitors (ICIs) and targeted therapy (TT) have improved the survival of people with metastatic melanoma. We assessed the feasibility, acceptability, and utility of a novel model of nurse-led, telehealth-delivered survivorship care (MELCARE) for this survivor group. METHO...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492451/ https://www.ncbi.nlm.nih.gov/pubmed/36136246 http://dx.doi.org/10.1007/s00520-022-07360-4 |
_version_ | 1784793484271550464 |
---|---|
author | Lai-Kwon, Julia Kelly, Brooke Lane, Sarah Biviano, Rebecca Bartula, Iris Brennan, Frank Kivikoski, Ingrid Thompson, Jake Dhillon, Haryana M. Menzies, Alexander Long, Georgina V. |
author_facet | Lai-Kwon, Julia Kelly, Brooke Lane, Sarah Biviano, Rebecca Bartula, Iris Brennan, Frank Kivikoski, Ingrid Thompson, Jake Dhillon, Haryana M. Menzies, Alexander Long, Georgina V. |
author_sort | Lai-Kwon, Julia |
collection | PubMed |
description | PURPOSE: Immune checkpoint inhibitors (ICIs) and targeted therapy (TT) have improved the survival of people with metastatic melanoma. We assessed the feasibility, acceptability, and utility of a novel model of nurse-led, telehealth-delivered survivorship care (MELCARE) for this survivor group. METHODS: People ≥ 18 years diagnosed with unresectable stage III or stage IV melanoma who were ≥ 6 months post initiation of ICI/TT with a radiological response suggestive of a long-term response to ICI/TT were recruited from a specialist melanoma centre in Australia. All participants received MELCARE, a nurse-led survivorship program involving two telehealth consultations 3 months apart, needs assessment using the Distress Thermometer (DT) and Problem List, and creation of a survivorship care plan. Feasibility, acceptability, and utility were assessed using rates of consent and study completion, time taken to complete each component of MELCARE, the Acceptability of Intervention Measure (AIM), and a customised utility survey. RESULTS: 31/54 (57%) people consented. Participants were male (21, 68%), with a median age of 67 (range: 46–82). Eleven (35%) were receiving/had received ipilimumab and nivolumab and 27 (87%) had ceased treatment. Feasibility was demonstrated with 97% completing MELCARE. Utility was demonstrated on a customised survey and supported by a reduction in the mean DT score (initial: 5.6, SD: 2.9; follow-up: 1.5, SD: 1.2). Acceptability was demonstrated on 3/4 AIM items. CONCLUSION: MELCARE was feasible and acceptable with high levels of utility. However, the consent rate was 57% indicating some people do not require support. Future studies should consider MELCARE’s optimal timing, resourcing, and cost-effectiveness. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00520-022-07360-4. |
format | Online Article Text |
id | pubmed-9492451 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-94924512022-09-22 Feasibility, acceptability, and utility of a nurse-led survivorship program for people with metastatic melanoma (MELCARE) Lai-Kwon, Julia Kelly, Brooke Lane, Sarah Biviano, Rebecca Bartula, Iris Brennan, Frank Kivikoski, Ingrid Thompson, Jake Dhillon, Haryana M. Menzies, Alexander Long, Georgina V. Support Care Cancer Research PURPOSE: Immune checkpoint inhibitors (ICIs) and targeted therapy (TT) have improved the survival of people with metastatic melanoma. We assessed the feasibility, acceptability, and utility of a novel model of nurse-led, telehealth-delivered survivorship care (MELCARE) for this survivor group. METHODS: People ≥ 18 years diagnosed with unresectable stage III or stage IV melanoma who were ≥ 6 months post initiation of ICI/TT with a radiological response suggestive of a long-term response to ICI/TT were recruited from a specialist melanoma centre in Australia. All participants received MELCARE, a nurse-led survivorship program involving two telehealth consultations 3 months apart, needs assessment using the Distress Thermometer (DT) and Problem List, and creation of a survivorship care plan. Feasibility, acceptability, and utility were assessed using rates of consent and study completion, time taken to complete each component of MELCARE, the Acceptability of Intervention Measure (AIM), and a customised utility survey. RESULTS: 31/54 (57%) people consented. Participants were male (21, 68%), with a median age of 67 (range: 46–82). Eleven (35%) were receiving/had received ipilimumab and nivolumab and 27 (87%) had ceased treatment. Feasibility was demonstrated with 97% completing MELCARE. Utility was demonstrated on a customised survey and supported by a reduction in the mean DT score (initial: 5.6, SD: 2.9; follow-up: 1.5, SD: 1.2). Acceptability was demonstrated on 3/4 AIM items. CONCLUSION: MELCARE was feasible and acceptable with high levels of utility. However, the consent rate was 57% indicating some people do not require support. Future studies should consider MELCARE’s optimal timing, resourcing, and cost-effectiveness. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00520-022-07360-4. Springer Berlin Heidelberg 2022-09-22 2022 /pmc/articles/PMC9492451/ /pubmed/36136246 http://dx.doi.org/10.1007/s00520-022-07360-4 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Research Lai-Kwon, Julia Kelly, Brooke Lane, Sarah Biviano, Rebecca Bartula, Iris Brennan, Frank Kivikoski, Ingrid Thompson, Jake Dhillon, Haryana M. Menzies, Alexander Long, Georgina V. Feasibility, acceptability, and utility of a nurse-led survivorship program for people with metastatic melanoma (MELCARE) |
title | Feasibility, acceptability, and utility of a nurse-led survivorship program for people with metastatic melanoma (MELCARE) |
title_full | Feasibility, acceptability, and utility of a nurse-led survivorship program for people with metastatic melanoma (MELCARE) |
title_fullStr | Feasibility, acceptability, and utility of a nurse-led survivorship program for people with metastatic melanoma (MELCARE) |
title_full_unstemmed | Feasibility, acceptability, and utility of a nurse-led survivorship program for people with metastatic melanoma (MELCARE) |
title_short | Feasibility, acceptability, and utility of a nurse-led survivorship program for people with metastatic melanoma (MELCARE) |
title_sort | feasibility, acceptability, and utility of a nurse-led survivorship program for people with metastatic melanoma (melcare) |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492451/ https://www.ncbi.nlm.nih.gov/pubmed/36136246 http://dx.doi.org/10.1007/s00520-022-07360-4 |
work_keys_str_mv | AT laikwonjulia feasibilityacceptabilityandutilityofanurseledsurvivorshipprogramforpeoplewithmetastaticmelanomamelcare AT kellybrooke feasibilityacceptabilityandutilityofanurseledsurvivorshipprogramforpeoplewithmetastaticmelanomamelcare AT lanesarah feasibilityacceptabilityandutilityofanurseledsurvivorshipprogramforpeoplewithmetastaticmelanomamelcare AT bivianorebecca feasibilityacceptabilityandutilityofanurseledsurvivorshipprogramforpeoplewithmetastaticmelanomamelcare AT bartulairis feasibilityacceptabilityandutilityofanurseledsurvivorshipprogramforpeoplewithmetastaticmelanomamelcare AT brennanfrank feasibilityacceptabilityandutilityofanurseledsurvivorshipprogramforpeoplewithmetastaticmelanomamelcare AT kivikoskiingrid feasibilityacceptabilityandutilityofanurseledsurvivorshipprogramforpeoplewithmetastaticmelanomamelcare AT thompsonjake feasibilityacceptabilityandutilityofanurseledsurvivorshipprogramforpeoplewithmetastaticmelanomamelcare AT dhillonharyanam feasibilityacceptabilityandutilityofanurseledsurvivorshipprogramforpeoplewithmetastaticmelanomamelcare AT menziesalexander feasibilityacceptabilityandutilityofanurseledsurvivorshipprogramforpeoplewithmetastaticmelanomamelcare AT longgeorginav feasibilityacceptabilityandutilityofanurseledsurvivorshipprogramforpeoplewithmetastaticmelanomamelcare |